Regeneron's Eylea combination therapy fails mid-stage study

(Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness.

Thailand confirms two cases of Zika-linked microcephaly - health ministry

BANGKOK (Reuters) - Thailand confirmed on Friday that Zika had caused two cases of microcephaly, a condition that results in babies being born with small heads, the first time microcephaly had been linked to Zika in Southeast Asia.

Zika-related birth defects likely higher than anticipated: panel

BOSTON (Reuters) - The risk posed by the Zika virus to developing fetuses is likely far greater than current estimates suggest, a top U.S. health official said on Thursday.